Philips (NYSE: PHG) and partners Cuviva and Vingmed were selected by Region Stockholm, via a Karolinska University Hospital-led tender, to deliver an advanced hospital-at-home program for up to 15,000 complex or chronic patients annually.
The up to eight-year agreement covers more than 2 million residents, using remote monitoring, vital-sign tracking, video consultations and secure chat to extend hospital-level oversight into patients’ homes and help ease pressure on hospitals and clinical staff.
Loading…
Loading translation…
AI-generated analysis. Not financial advice.
Positive
Up to eight-year hospital-at-home agreement across Region Stockholm
Covers more than 2 million residents with remote monitoring capability
Targets up to 15,000 complex or chronic patients annually at home
Consortium model leverages Philips, Cuviva and Vingmed specializations
Annual patients capacity
up to 15,000 patients per year
Hospital-at-home program coverage in Region Stockholm
Agreement duration
up to eight years
Consortium agreement term with Region Stockholm
Regional population covered
more than 2 million people
Population in Region Stockholm supported by the initiative
$25.23
Last Close
Volume
Volume 1,219,570 is slightly below 20-day average 1,324,355 (relative volume 0.92).
normal
Technical
Shares at 25.23 are trading below the 200-day MA of 28.09, and about 24.54% under the 52-week high 33.435.
PHG was down 1.06% pre-news with mixed moves across key Medical Devices peers: some up (e.g., DXCM +2.87%, ZBH +0.83%) and others down (e.g., PODD -1.63%, STE -1.53%, SNN -0.71%), indicating stock-specific rather than sector-wide dynamics.
Date
Event
Sentiment
Move
Catalyst
May 08
AGM approvals
Neutral
+0.2%
Shareholders approved all AGM proposals, including key board appointments.
May 06
Earnings update
Positive
+3.0%
Reported strong order intake, comparable sales growth and margin expansion in Q1.
Apr 23
Product launch
Positive
-2.2%
Launched Bridge Plus Occlusion Balloon for managing rare SVC tears in lead extraction.
Apr 22
Regulatory clearance
Positive
-0.8%
Received FDA 510(k) clearance for Rembra CT/RT platform for advanced CT imaging.
Apr 16
AI CT clearance
Positive
-1.6%
Gained FDA 510(k) clearance for AI-powered Spectral CT Verida system.
Pattern Detected
Recent product and regulatory clearances often saw negative next-day moves despite positive fundamentals, while broader corporate or financial updates tended to align with modest gains.
Recent Company History
Over the last months, Philips has combined corporate governance stability with product innovation. Shareholders approved all AGM proposals on May 8, 2026, with a slight positive price reaction. Earlier, a Q1 update citing strong order intake, comparable sales growth and margin expansion produced a +2.95% move. In contrast, multiple positive device launches and FDA 510(k) clearances in April, including CT platforms and the Bridge Plus Occlusion Balloon, were followed by negative short-term reactions, highlighting occasional divergence between innovation news and price action.
This announcement highlights a sizeable, long-duration engagement in hospital-at-home care for Region Stockholm, potentially covering more than 2 million people and up to 15,000 patients annually over an up to eight-year term. It reinforces Philips’ positioning in remote monitoring, data integration and connected care. In reviewing this development, investors may consider how it complements prior CT and monitoring innovations, the pace of regional-scale rollouts, and how such contracts influence order intake and margins over time.
ecg
medical
“including waveform data such as ECG and oxygen saturation.”
An ECG (electrocardiogram) records the heart’s electrical activity through small sensors on the skin and produces a waveform that shows heart rate, rhythm and signs of stress or damage—think of it as a seismograph for the heart’s electrical signals. Investors care because ECGs are central to diagnosing and monitoring cardiac safety in clinical trials, required for regulatory approval of many drugs and devices, and drive demand for related medical equipment and services.
pulse oximetry
medical
“including ECG, blood pressure and pulse oximetry – and for the deployment”
Pulse oximetry is a noninvasive way to estimate how much oxygen is in a person’s blood using a small sensor—commonly clipped to a finger, toe, or earlobe—that also reads pulse rate. For investors, it matters because this measurement is a common feature in medical and consumer health devices; its accuracy, regulatory status, and demand influence product adoption, sales, and the perceived reliability of companies that make or use the technology.
wearable technology
technical
“working alongside leading sensor and wearable technology providers – to deliver”
Wearable technology are electronic devices you wear on your body—like watches, fitness bands, smart clothing or health patches—that collect data, deliver alerts, and run apps while moving with the user. Investors care because these devices create ongoing revenue from hardware, subscriptions and services, generate valuable user data that can drive new products or partnerships, and expose companies to regulatory, privacy and manufacturing risks similar to any consumer-health gadget.
interoperability
technical
“Philips contributes to its global expertise in patient monitoring, interoperability, and data”
Interoperability is the ability of different systems, devices, or software to work together smoothly and share information easily. It matters to investors because it enables more efficient operations, better data sharing, and faster decision-making across various platforms or technologies. When systems are interoperable, they can connect and communicate as if they were part of a single, unified system, reducing complexity and increasing overall effectiveness.
AI-generated analysis. Not financial advice.
05/18/2026 – 04:00 AM
May 18, 2026
Philips-led consortium selected through Karolinska University Hospital-led Region Stockholm tender to deliver advanced remote monitoring for complex patients
Stockholm, Sweden – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that a consortium composed of Philips, Cuviva and Vingmed has been selected to support Region Stockholm’s hospital-at-home initiative, enabling hospital-level care to be delivered in patients’ homes across the region. The consortium was selected through a tender led by Karolinska University Hospital for an advanced remote-monitoring program serving patients with complex or chronic conditions.
The up to eight-year agreement will support care for more than 2 million people in the Stockholm region and is Region Stockholm’s first region-wide hospital-at-home initiative, designed to extend hospital-led care into patients’ homes through a coordinated, multi-partner model. By combining advanced remote-monitoring technologies with digitally connected care pathways, the program enables patients across Region Stockholm to receive high-quality care at home while helping reduce pressure on hospitals and clinical staff throughout the region.
Delivering hospital-level care at home across Region Stockholm
Through this initiative, publicly owned hospitals and primary care facilities within Region Stockholm will be able to monitor patients with complex or chronic conditions continuously in their homes by enabling hospital-led clinical oversight through digital connected care. Many of these patients require continuous monitoring of key clinical parameters, including waveform data such as ECG and oxygen saturation. This data will be securely available in near real time to healthcare professionals across hospital and primary care settings throughout the region.
The solution also enables direct patient-clinician interaction through assigned care pathways, video consultations, and secure chat functionality, while tracking a wide range of vital signs to support ongoing assessment and early detection of clinical deterioration. Implemented as a region-wide program, the initiative will serve patients across the greater Stockholm area and directly support Region Stockholm’s healthcare priorities – responding to rising demand from an aging population, addressing workforce shortages, and promoting supporting equitable access to high-quality care in both urban and remote communities.
Accelerating a new era of connected care at regional scale
The consortium brings together Philips, Cuviva, and Vingmed – working alongside leading sensor and wearable technology providers – to deliver an advanced, patient-centered hospital-at-home solution at a regional scale. Philips contributes to its global expertise in patient monitoring, interoperability, and data integration. Cuviva, a Swedish digital health company, serves as the core technology provider, delivering a secure, advanced and fully integrated IT platform that enables structured, scalable hospital-at-home care through digital monitoring, real-time communication, and smooth integration with the hospital’s digital infrastructure. Vingmed, a Nordic healthcare technology specialist, is responsible for the clinical measurement devices in the home – including ECG, blood pressure and pulse oximetry – and for the deployment and lifecycle management of this equipment across the region.
Together, the consortium will support Region Stockholm in realizing its vision for the future of care: extending hospital-level oversight into the home across the region to help patient outcomes while easing the burden on clinicians and hospital infrastructure.
A model for the future of healthcare
“This collaboration represents a shift in how we deliver and experience healthcare in Sweden,” said Julia Strandberg, Chief Business Leader, Connected Care at Philips. “Together with our consortium partners, we’re combining digital innovation, clinical expertise, and remote monitoring to reach more patients, ease pressure on healthcare systems, and create a scalable model for connected, sustainable, patient-centered care across Europe.”
For further information, please contact:
Eeva Vesander
Marketing Leader
Philips Health Systems Nordics
Tel.: +46723713960
Email: eeva.vesander@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2025 sales of EUR 18 billion and employs approximately 64,300 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Karolinska University Hospital
FAQ
What did Philips (NYSE: PHG) announce about hospital-at-home care in Region Stockholm on May 18, 2026?
Philips announced leading a consortium to power Region Stockholm’s new hospital-at-home program. According to Philips, the up to eight-year agreement brings advanced remote monitoring and connected care pathways to complex and chronic patients treated at home across the region.
How many patients could Philips’ hospital-at-home solution in Region Stockholm support each year?
The program is designed to support hospital-at-home care for up to 15,000 patients annually. According to Philips, these patients typically have complex or chronic conditions requiring continuous remote monitoring and digital interaction with clinicians overseeing their care from hospital and primary care settings.
What technologies will Philips provide for the Region Stockholm hospital-at-home initiative (PHG)?
Philips will provide remote monitoring, data integration and interoperability technology within a multi-partner platform. According to Philips, the solution enables near real-time access to ECG, oxygen saturation and other vital signs, plus video consultations and secure chat between patients and clinicians across the region.
Who are the consortium partners with Philips (PHG) for the Region Stockholm hospital-at-home program?
Philips is working with Cuviva and Vingmed in a three-party consortium. According to Philips, Cuviva supplies the core digital platform, while Vingmed provides home clinical measurement devices and manages deployment and lifecycle of ECG, blood pressure and pulse oximetry equipment region-wide.
How many people in Region Stockholm are covered by Philips’ hospital-at-home agreement?
The agreement covers more than 2 million people living in the Stockholm region. According to Philips, publicly owned hospitals and primary care facilities can use the platform to monitor eligible patients at home, helping address aging populations, workforce shortages and equitable access to high-quality care.
How does Philips’ hospital-at-home project in Stockholm aim to impact hospitals and clinical staff?
The project aims to ease pressure on hospitals and clinical staff by shifting care into homes. According to Philips, continuous remote monitoring, digital communication tools and coordinated care pathways support early detection of deterioration while maintaining hospital-led oversight outside traditional inpatient settings.